ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC 50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently In Vitro ATX inhibitor 5 (compound 10g) (IC 50 s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC). ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: CFs and t-HSC/Cl-6 cells Concentration: 0.0001, 0.01, 1, 100, 10000 µM Incubation Time: 48 hours Result: Displayed activities against CFs and t-HSC/Cl-6 cells with IC 50 s of 1.21 and 0.78 µM, respectively. In Vivo ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Konmin mice (8-week old, 22-25 g) Dosage: 20, 40 mg/kg Administration: Orally; once daily for two weeks Result: Prominently reduced CCl4-induced hepatic fibrosis level. Form:Solid IC50& Target:Autotaxin